Buprenorphine/Naloxone Treatment for Opioid Dependence-Experiment I(2) - 2

University of Colorado Denver (CU Denver) logo

University of Colorado Denver (CU Denver)

Status and phase

Withdrawn
Phase 2

Conditions

Heroin Dependence
Opioid-Related Disorders

Treatments

Drug: Heroin Dependence

Study type

Interventional

Funder types

Other
NIH

Identifiers

NCT00000327
R01DA011160 (U.S. NIH Grant/Contract)
NIDA-11160-2
R01-11160-2

Details and patient eligibility

About

The purpose of this study is to compare the clinical efficacy of daily vs. 3-day (MWF) buprenorphine/naloxone combination tablet administration and determine whether outcomes are improved when using a 3-day schedule in which all doses are ingested at the clinic vs. one in which take-home doses are given on intervening days.

Full description

Mon/Wed/Fri dosing with the 8 mg buprenorphine/naloxone tablet is as safe and effective as daily dosing and is preferred by patients to daily dosing. Multiple doses of the combination tablet (e.g. 16mg, 24mg) are well tolerated by patients. A 3 day schedule with take-outs is as effective as a 3-day schedule in which all medication is ingested at the clinic

Sex

All

Ages

18 to 62 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Individual must be currently dependent and meet FDA criteria for narcotic maintenance treatment. Co-morbid substance abuse or dependence disorders may also be present. Individuals must be healthy despite drug dependency.

Exclusion criteria

Individuals with evidence of an active Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) Axis I psychiatric disorder (e.g., psychosis, manic-depressive illness, organic psychiatric disorders), significant medical illness (e.g. liver or cardiovascular disease) or pregnant female subjects are excluded from study participation.

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems